AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$ANTX

Williams Sarah Joanne sold $2K of ANTX

Williams Sarah Joanne (Principal Accounting Officer) sold 272 shares of AN2 Therapeutics, Inc. (ANTX) at $5.53 on 2026-09-01.

Original reporting
SEC EDGAR · Williams Sarah Joanne
Published Sep 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANTX
Neutral
high confidence
Mentioned
$ANTX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANTXNeutralLow
01

Why it matters

The transaction is a routine sale by a senior officer, with limited market impact.

02

Market read

Minor insider sell; low relevance for traders.

03

What to watch

Potential upcoming dilution or compensation changes not disclosed.

Relevance 3/10Novelty 3/10Timing: filed Sep 4 2026

Background

SEC Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$ANTXNeutralHigh confidence
Context

Principal Accounting Officer sold 272 shares for $1,504 on Sep 1, 2026, reducing her stake.

Expected impact

No significant impact expected.

Evidence & confidence

The sale amount is small relative to total holdings and market cap; typical routine transaction.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could signal insider concern, but size is too small to act on.

Key entities

  • Officer
    Williams Sarah Joanne

    Principal Accounting Officer of AN2 Therapeutics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANTX insider trading history →

Related articles

AUG 11
$ANTXMed

AN2 Therapeutics, Inc. (ANTX): Results of Operations and Financial Condition

AN2 Therapeutics, Inc. (ANTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights Expanding Phase 2 study start-up activities to support global trial of oral epetraborole in polycythemia vera Enrollment ongoing in Phase 2 investigator-initi

SEC EDGAR 8-K6 min